Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?
- 8 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Thrombosis and Thrombolysis
- Vol. 52 (2), 584-589
- https://doi.org/10.1007/s11239-020-02354-7
Abstract
Venous thromboembolism is a common complication of patients with hematologic malignancies, due both to release of procoagulant factors by tumor cells and to external factors, such us drugs. In multiple myeloma patients, the risk is increased by use of immunomodulants, especially when associated to multidrug therapy, during the induction phase. Prevention of venous thromboembolism in myeloma patients is highly recommended but specific guidelines are still lacking. The most common approach is to stratify the thrombotic risk according to individual, myeloma-related and therapy-related risk factors and to use aspirin for all patients, except those with two or more thrombotic risk factors who should be treated with traditional oral or parenteral anticoagulant. A more controversial approach indicates for prophylaxis either anticoagulant or aspirin, regardless of risk stratification. Recent trials investigate prophylaxis in myeloma patients with direct oral anticoagulants, based on studies showing efficacy and safety of this new class of drugs in the treatment and prophylaxis of thrombosis in patients with any malignancy. The results of these trials are encouraging but they need to be confirmed by larger studies. An international consensus about best prophylaxis to prevent venous thromboembolism in patients with multiple myeloma on treatment is still missing. Therefore, thrombosis in multiple myeloma remains an ongoing issue.Keywords
This publication has 29 references indexed in Scilit:
- Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerationsBritish Journal of Haematology, 2018
- Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathyJournal of Thrombosis and Haemostasis, 2016
- Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based studyBlood, 2010
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacyAnnals of Oncology, 2006
- Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2006
- Malignancies, Prothrombotic Mutations, and the Risk of Venous ThrombosisJAMA, 2005
- Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulationBritish Journal of Haematology, 2004
- Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasoneAnnals of Hematology, 2004
- Thalidomide protects endothelial cells from doxorubicin‐induced apoptosis but alters cell morphologyJournal of Thrombosis and Haemostasis, 2004